Labs Partner with Pharma for New Companion Diagnostics Tests
Specially crafted lab tests speed up adoption of novel drug treatments.
Specially crafted lab tests speed up adoption of novel drug treatments.
Cost cutting and restructuring has become the order of the day for many lab companies.
Roche and Abbott received the most approvals for new lab tests last year.
Key Dx announcements last week involved companion diagnostics, liquid biopsy assays, and an RUO leukemia test.
Though the federal spending bill passed at the end of December offers another year’s reprieve from PAMA price cuts, SALSA was not included.